Allogeneic leukocytes in cardiac surgery: Good or bad?

Area of Science:

• Immunology
• Cardiovascular Surgery
• Transfusion Medicine

Background:

• Cardiac surgery necessitates significant allogeneic blood product transfusion.
• Allogeneic blood products contain leukocytes, implicated in postoperative complications.
• Transfusion-Related Immunomodulation (TRIM) is a potential consequence of leukocyte exposure.

Purpose of the Study:

• To review the role of blood transfusions in cardiac surgery.
• To investigate the specific impact of allogeneic leukocytes on postoperative complications.
• To analyze the association between leukocyte transfusion and inflammatory responses.

Main Methods:

• Review of randomized controlled trials (RCTs) investigating leukocyte effects in red blood cells (RBCs).
• Analysis of cardiac surgery studies comparing leukocyte-reduced RBCs versus leukocyte-containing RBCs.
• Examination of inflammatory mediator concentrations in patients with postoperative complications.

Main Results:

• Leukocyte-reduced RBCs were associated with reduced postoperative infections and mortality in cardiac surgery patients.
• Patients receiving leukocyte-containing RBCs showed higher rates of infection and multiple organ dysfunction syndrome (MODS).
• Elevated inflammatory mediators were observed in patients experiencing postoperative complications.

Conclusions:

• Leukocyte-containing transfusions during cardiac surgery may induce a secondary inflammatory insult.
• Reducing leukocyte content in transfused RBCs may mitigate postoperative complications.
• Allogeneic leukocytes are a significant factor in adverse outcomes following cardiac surgery.